ORPHA.CO
Price:
$1120
Market Cap:
$46.72M
Orphazyme A/S does not have significant operations. Previously, the company was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.[Read more]
Industry
Biotechnology
IPO Date
2017-11-21
Stock Exchange
CPH
Ticker
ORPHA.CO
According to Orphazyme A/S’s latest financial reports and current stock price. The company's current Enterprise Value is 32.74M. This represents a change of -99.91% compared to the average of 38.17B of the last 4 quarters.
The mean historical Enterprise Value of Orphazyme A/S over the last ten years is 744.42B. The current 32.74M Enterprise Value has changed -99.56% with respect to the historical average. Over the past ten years (40 quarters), ORPHA.CO's Enterprise Value was at its highest in in the March 2020 quarter at 2.32T. The Enterprise Value was at its lowest in in the September 2022 quarter at -38918000.00.
Average
744.42B
Median
803.30B
Minimum
-77916000.00
Maximum
1.90T
Discovering the peaks and valleys of Orphazyme A/S Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 202.81%
Maximum Annual Enterprise Value = 1.90T
Minimum Annual Increase = -1052318.38%
Minimum Annual Enterprise Value = -77916000.00
Year | Enterprise Value | Change |
---|---|---|
2023 | 46.54B | 50.14% |
2022 | 31.00B | -94.83% |
2021 | 599.23B | -68.51% |
2020 | 1.90T | 31.39% |
2019 | 1.45T | 63.63% |
2018 | 885.00B | -4.34% |
2017 | 925.14B | 17.59% |
2016 | 786.75B | -4.04% |
2015 | 819.85B | -1052318.38% |
2015 | -77916000.00 | 202.81% |
The current Enterprise Value of Orphazyme A/S (ORPHA.CO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
225.59B
5-year avg
805.51B
10-year avg
744.42B
Orphazyme A/S’s Enterprise Value is less than Zealand Pharma A/S (51.91B), less than Ambu A/S (34.00B), less than BioPorto A/S (708.29M), less than Bavarian Nordic A/S (15.58B), less than Genmab A/S (93.09B),
Company | Enterprise Value | Market cap |
---|---|---|
51.91B | $58.67B | |
34.00B | $33.92B | |
708.29M | $806.48M | |
15.58B | $16.27B | |
93.09B | $96.40B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Orphazyme A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Orphazyme A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Orphazyme A/S's Enterprise Value?
What is the highest Enterprise Value for Orphazyme A/S (ORPHA.CO)?
What is the 3-year average Enterprise Value for Orphazyme A/S (ORPHA.CO)?
What is the 5-year average Enterprise Value for Orphazyme A/S (ORPHA.CO)?
How does the current Enterprise Value for Orphazyme A/S (ORPHA.CO) compare to its historical average?